TRKB
8 drugs Oncology
5
approved indications
8
Approved Drugs
8
Companies
14
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (8 companies)
✓ All 8 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (14 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
EXELIXIS INC 1 drug
Bayer 1 drug
Roche 1 drug
By Therapeutic Area
Other 5 drugs
Oncology 3 drugs
By Therapeutic Area
Other 5 drugs
CABOMETYX, VITRAKVI, ROZLYTREK, COMETRIQ +1 more
Oncology 3 drugs
AUGTYRO, IBTROZI, LORBRENA
Indications Treated
ROS1-positive metastatic non-small cell lung cancer (NSCLC) in adultsNTRK gene fusion-positive solid tumors in adult and pediatric patients older than 1 monthMedullary Thyroid CancerNon-Small Cell Lung CancerAdvanced renal cell carcinomaHepatocellular carcinoma previously treated with sorafenibLocally advanced or metastatic differentiated thyroid cancerWell-differentiated pancreatic neuroendocrine tumorsWell-differentiated extra-pancreatic neuroendocrine tumorsSolid tumors with a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutationMetastatic solid tumors with NTRK gene fusionSolid tumors with NTRK gene fusion where surgical resection is likely to result in severe morbiditySolid tumors with NTRK gene fusion that have progressed following treatment or have no satisfactory alternative treatmentsSolid Tumors